Targeted therapies for breast cancer: What are they and how do they work?
What are targeted therapies?
Targeted therapies are a type of cancer treatment that focuses on specific proteins or genes that play a role in promoting cancer growth. Unlike chemotherapy, which targets rapidly dividing cells in the body, targeted therapies aim to identify and attack specific molecules that are involved in the growth and spread of cancer cells.
Targeted therapies can take various forms, including monoclonal antibodies, small molecule inhibitors, and immunotherapies. They can be used alone or in combination with other treatments, such as chemotherapy and radiation. They work by interrupting specific signaling pathways that are critical for cancer cell growth and survival.
How do targeted therapies work in breast cancer?
Targeted therapies have revolutionized the treatment of breast cancer in recent years. They are now used in various stages of breast cancer, including early-stage hormone receptor-positive breast cancer, HER2-positive breast cancer, and triple-negative breast cancer.
Hormone receptor-positive breast cancer: Hormone receptor-positive breast cancer is the most common type of breast cancer, accounting for about 75% of all cases. These cancers are fueled by hormones like estrogen and progesterone. Targeted therapies for hormone receptor-positive breast cancer include drugs like tamoxifen and aromatase inhibitors, which work by blocking the hormones from binding to cancer cells and slowing down their growth.
HER2-positive breast cancer: About 15-20% of breast cancers are HER2-positive, meaning they overproduce a protein called human epidermal growth factor receptor 2 (HER2). HER2-positive breast cancers tend to be more aggressive and have a higher risk of recurrence than other types of breast cancer. Targeted therapies for HER2-positive breast cancer include drugs like trastuzumab, pertuzumab, and ado-trastuzumab emtansine (T-DM1), which all target the HER2 protein and inhibit its activity.
Triple-negative breast cancer: Triple-negative breast cancer is a subtype of breast cancer that lacks hormone receptors and does not overproduce HER2. It tends to be more aggressive and harder to treat than other types of breast cancer. Targeted therapies for triple-negative breast cancer are still being developed, but recent advances have shown promise. Immunotherapies like checkpoint inhibitors, which work by enhancing the body's immune response against cancer cells, have shown significant benefits in some patients with triple-negative breast cancer.
What are the benefits and risks of targeted therapies?
Targeted therapies offer several benefits over traditional chemotherapy, including more specific targeting of cancer cells, fewer side effects, and higher response rates in some cases. However, they also come with risks and limitations.
One of the main challenges of targeted therapies is drug resistance. Cancer cells can become resistant to targeted therapies over time by developing new mutations or finding alternative pathways to bypass the targeted molecule. This can lead to disease progression and the need for alternative treatment options.
Another challenge is the high cost of targeted therapies, which can make them inaccessible to some patients. Additionally, targeted therapies may not be effective in all patients or may cause side effects like fatigue, nausea, and skin rash.
Conclusion
Targeted therapies have revolutionized the treatment of breast cancer by providing more precise and effective treatment options than traditional chemotherapy. They work by targeting specific molecules involved in cancer growth and can be used in various stages of breast cancer, including hormone receptor-positive, HER2-positive, and triple-negative breast cancer.
While targeted therapies offer many benefits, they also come with limitations, including drug resistance and high costs. Therefore, it is important for patients to work closely with their healthcare team to determine the most appropriate treatment plan based on their unique circumstances and medical history.